Download presentation
Presentation is loading. Please wait.
Published byYandi Gunawan Modified over 6 years ago
1
A phase 2 study of single-agent carfilzomib (PX A1) in patients with relapsed and refractory multiple myeloma by David S. Siegel, Thomas Martin, Michael Wang, Ravi Vij, Andrzej J. Jakubowiak, Sagar Lonial, Suzanne Trudel, Vishal Kukreti, Nizar Bahlis, Melissa Alsina, Asher Chanan-Khan, Francis Buadi, Frederic J. Reu, George Somlo, Jeffrey Zonder, Kevin Song, A. Keith Stewart, Edward Stadtmauer, Lori Kunkel, Sandra Wear, Alvin F. Wong, Robert Z. Orlowski, and Sundar Jagannath Blood Volume 120(14): October 4, 2012 ©2012 by American Society of Hematology
2
Survival. Survival. PFS (A) and OS (B) in response evaluable patients (n = 257) treated with single-agent carfilzomib. David S. Siegel et al. Blood 2012;120: ©2012 by American Society of Hematology
3
Responses according to demographic and baseline disease characteristics.
David S. Siegel et al. Blood 2012;120: ©2012 by American Society of Hematology
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.